Weekly NADAC Price Changes
A weekly executive brief covering the pricing movements that matter most to market strategy and reimbursement planning.
- Published NDCs
- 30,167
- Price increases
- 3
- Price decreases
- 0
- Unchanged prices
- 30,091
NADAC weekly update: 3 NDCs changed — 2026-10-28
The CMS publication dated 2026-10-28 contains 30,167 priced NDCs in our data. Of the 30,094 NDCs also priced in the 2026-10-21 publication, 3 changed and 30,091 were unchanged. This edition reports the available updates; a small number of changes does not establish a market-wide trend.
Key takeaways
- 3 NDCs increased and 0 decreased compared with the 2026-10-21 publication.
- 30,091 comparable NDCs retained the same published price.
- 73 NDCs have no matching price in the 2026-10-21 publication and are excluded from change calculations.
- One tracked change: INGREZZA 40 MG CAPSULE (NDC 70370204001) moved from $258.9417 to $270.5863 per pricing unit (+4.5%).
What to watch
Review affected NDCs
Check the exact NDC and pricing unit against your purchasing records before applying an update.
Next publication
The next ingested CMS publication will receive its own edition, even if comparable prices remain unchanged.
Top 3 NDCs by weekly price movement
Up to 10 changed products are shown. Each edition preserves its published price comparison.
| Drug | Manufacturer | NDC | Prev. price | Current price | Change |
|---|---|---|---|---|---|
| INGREZZA 40 MG CAPSULE | Neurocrine Biosciences, Inc. | 70370204001 | $258.9417 | $270.5863 | +4.5% |
| INGREZZA 80 MG CAPSULE | Neurocrine Biosciences, Inc. | 70370108001 | $283.3240 | $291.8152 | +3.0% |
| INGREZZA 60 MG CAPSULE | Neurocrine Biosciences, Inc. | 70370106001 | $283.3240 | $291.8152 | +3.0% |
Drug market summaries
Manufacturer movement
Therapeutic class shifts
Notes and methodology
How the weekly brief calculations were ranked, aggregated, and preserved for archive consistency.
Publication comparison
Prices are compared between the two CMS publication dates shown above, using weekly history snapshots. An unchanged effective date does not mean a publication is missing. NDCs absent from the previous publication are excluded from change calculations; missing prices are not counted as unchanged.
Top mover ranking
The Top 3 table ranks NDCs by absolute weekly impact: the change in unit price multiplied by dispensing exposure when available. The current release had 3 NDCs with a measurable publication-to-publication change.
Segment summaries
Drug markets, manufacturers, and therapeutic classes aggregate the same NDC-level deltas. Average move is the mean percent change, while impact is the summed dollar-weighted effect using dispensing-volume exposure when the volume table is available.
Headline cards and archive stability
In editions with headline cards, most pressured class selects the largest positive class impact, and largest manufacturer swing selects the manufacturer with the largest aggregate absolute impact. Every weekly brief stores a frozen snapshot so archived pages do not drift when live NADAC data changes.
More archived editions
Each edition is permanently archived under its release date.
Week of October 21, 2026
NADAC Week of Oct 21: Balanced Price Movement Masks Concentrated Spikes in Biologics and Glucagon
The October 21, 2026 NADAC release covered 30,095 NDCs, with 29,992 eligible for week-over-week comparison. Of these, 28,712 (95.7%) changed price, split nearly evenly between 14,883 increases and 13,829 decreases, alongside 1,280 unchanged NDCs and 103 without a prior comparison. This near-even split signals broad repricing activity rather than a directional market-wide trend. The largest single dollar movements were concentrated in a handful of specialty products: a $1.8M increase tied to a single Ofatumumab (Kesimpta) NDC and a $853.2K decline led by Glucagon products, particularly the Amphastar emergency kit (-12.8%). Manufacturer-level activity shows Novartis and AbbVie posting the largest aggregate upward swings ($1.9M and $1.2M respectively) across dozens of products, while Amphastar and Prasco Laboratories saw net declines. Therapeutic class data shows the top class by dollar impact, CD20-directed Cytolytic Antibody, reflects just one drug, underscoring that headline-level 'most pressured class' figures can be driven by a single product rather than category-wide pressure. In contrast, broader classes like alpha-Adrenergic Agonist (252 drugs) and Progestin (125 drugs) show more distributed movement, better reflecting true market breadth this week.
Week of October 14, 2026
NADAC weekly update: no price changes among comparable NDCs — 2026-10-14
The CMS publication dated 2026-10-14 contains 30,031 priced NDCs in our data. Of the 30,027 NDCs also priced in the 2026-10-07 publication, 0 changed and 30,027 were unchanged. This edition reports the available updates; a small number of changes does not establish a market-wide trend.
Week of October 7, 2026
NADAC weekly update: 2 NDCs changed — 2026-10-07
The CMS publication dated 2026-10-07 contains 30,048 priced NDCs in our data. Of the 29,987 NDCs also priced in the 2026-09-30 publication, 2 changed and 29,985 were unchanged. This edition reports the available updates; a small number of changes does not establish a market-wide trend.
Explore the broader trend ecosystem
Trends overview
Broader market movement and volatility across the full NADAC dataset.
Manufacturers
Compare suppliers and pricing dispersion across product portfolios.
Drug markets
Review generic alternatives by therapeutic market and current pricing.
Therapeutic classes
See category-level swings by prescribing class and market segment.
Understanding NADAC pricing
A primer on how NADAC works and why weekly movement matters.
Methodology
How the data is normalized and aggregated for public reporting.